Article 4 Grand Pharma attaches great importance to information security and strives to ensure the confidentiality, integrity and availability of the Company's information assets. The Company undertakes to implement the following principles and measures in all business activities:

(i) Continuous Improvement of Information Security Management System.

(ii) Employment information, such as employer, job title and employment history.


(iii) Information obtained through communications, such as comments, questions, feedback and other content provided when using website functions.

(iv) Adverse event information, such as age, weight, medical history, allergy history, description of adverse reactions and medication usage.

(v) Other sensitive personal information necessary for fulfilling statutory obligations or conducting specific business activities, such as clinical trial data, patient health records, and personal identity and health information contained in pharmacovigilance reports.

Article 6 The Company may use personal information for the following purposes:

(i) Reviewing opinions or inquiries submitted by data subjects and providing corresponding service supm" ﻛﺪ p



- Personal Informa
- Our pr
data s ect;
- The
nece
- The
inform

(iv) Right
purp
pro
ex
is

(v)

(vi)

(vii)

Article 11 Where the Company conducts any form of cross-border data transfer (including provision of personal information, important corporate data, technical secrets or other assets to overseas recipients) it shall strictly comply with the applicable laws and regulations of both the data exporting and receiving jurisdictions. For cross-border transfers c t¡6Ąc e

[redacted]

(viii) Low ecological footprint. Requiring (own/third-party) AI data centers/models to have a low ecological footprint, considering energy efficiency and sustainability in tech selection and deployment.

(ix) Not using illegal AI systems. The Company does not use or deploy AI systems that involve manipulative behavior, exploitation of vulnerabilities, social scoring or unauthorized biometric surveillance, When using AI systems, the Company shall comply with the provisions of Chinese laws and regulations, including the Interim Measures for the Management of Generative Artificial Intelligence Services, as well as other